Pamidronate treatment of osteogenesis imperfecta - Lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response

Journal of Pediatric Endocrinology and Metabolism

Volumn 15, Issue 2, 2002, Pages 163-174

  Zacharin, Margaret ^a   Bateman, John ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Collagen mutation; Osteogenesis imperfecta; Pamidronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN; COLLAGEN TYPE 1; PAMIDRONIC ACID;

ADOLESCENT; ALPHA CHAIN; ARTICLE; BONE DENSITY; BONE MALFORMATION; BONE MINERAL; BONE PAIN; BONE TURNOVER; CHILD; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL OBSERVATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTROPHORETIC MOBILITY; FEMALE; FRACTURE; GENE MUTATION; HEIGHT; HUMAN; JOINT MOBILITY; LUMBAR SPINE; MALE; ONSET AGE; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PHENOTYPE; PROTEIN SECRETION; PROTEIN STRUCTURE; QUALITY OF LIFE; SCORING SYSTEM; SKIN BIOPSY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VERTEBRA;

EID: 0036002592     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2002.15.2.163     Document Type: Article

References (55)

1. Molecular basis of osteogenesis imperfecta and related disorders of bone
2. Osteogenesis imperfecta: Translation of mutation to phenotype
3. Abnormal type I collagen metabolism by cultured fibroblasts in lethal perinatal osteogenesis imperfecta
4. Collagen defects in lethal perinatal osteogenesis imperfecta
5. Multiexon deletions in the type I collagen COLIA2 gene in osteogenesis imperfecta type IB. Molecules containing the shortened alpha2(I) chains show differential incorporation into the bone and skin extracellular matrix
6. Mutations in type I procollagen that cause osteogenesis imperfecta. Effects of the mutations on the assembly of collagen into fibrils, the basis of phenotypic variations and potential antisense therapies
7. Osteogenesis imperfecta type I is commonly due to a COL1A1 null allele of type I collagen
8. Osteogenesis imperfecta type I: Molecular heterogeneity for COL1A1 null alleles of type I collagen
9. Osteogenesis imperfecta: An expanding panorama of variants
10. Genetic heterogeneity in osteogenesis imperfecta
11. Clinical variability in osteogenesis imperfecta. Variable expressivity or genetic heterogeneity
12. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
13. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta
14. Bisphosphonates: Mechanisms of action
15. Molecular mechanisms of action of bisphosphonates
16. Bisphosphonates: From the laboratory to the clinic and back again
17. Protein gerangylgerangulation is required for osteoclast formation, function and survival: Inhibition by bisphosphonates and GGTI-298
18. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
19. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures
20. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
21. Bone histomorphometric analysis in osteogenesis imperfecta
22. Increased bone turnover with decreased bone formation in osteoblasts in children with osteogenesis imperfecta tarda
23. Failure of anabolic steroids in the therapy of osteogenesis imperfecta: A clinical, metabolic and biochemical study
24. Lack of effects of human calcitonin in osteogenesis imperfecta
25. Therapy of osteogenesis imperfecta with synthetic salmon calcitonin
26. Effects of long-term calcitonin therapy by injections and nasal spray on the incidence of fractures in osteogenesis imperfecta
27. Intravenous pamidronate treatment of osteogenesis imperfecta
28. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta
29. Long-term effects of continuous bisphosphonate therapy in children with vertebral osteoporosis
30. Beneficial effect of bisphosphonate during 5 years of treatment of severe osteogenesis imperfecta
31. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate
32. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients
33. Bisphosphonate therapy for severe osteogenesis imperfecta
34. The use of bisphosphonates in children with osteogenesis imperfecta
35. 14C] proline dual-labeling and polyacrylamide gel electrophoresis
36. Characterization of a type I collagen alpha 2(I) glycine-586 to valine substitution in osteogenesis imperfecta type IV. Detection of the mutation and prenatal diagnosis by a chemical cleavage method
37. The mineralization density of iliac crest bone from children with osteogenesis imperfecta
38. The microscopic structure of bone in normal children and patients with osteogenesis imperfecta: A survey using back-scattered electron imaging
39. Osteoporotic fractures: Background and prevention strategies
40. Bone mineral content and density in healthy subjects and in osteogenesis imperfecta
41. Bone mineral density in children with mild osteogenesis imperfecta
42. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study
43. Prophylaxis and treatment of osteoporosis
44. The crippling consequences of fractures and their impact on quality of life
45. Evaluation of adverse health outcomes associated with vertebral fractures
46. Costs and health effects of osteoporotic fractures
47. Intravenous pamidronate treatment of polyostotic fibrous dysplasia
48. Intravenous pamidronate in juvenile osteoporosis
49. Effect of oral alendronate on bone mineral density and the incidence of fractures in post menopausal osteoporosis
50. Multinational, placebo controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass; results of the FOSIT study
51. Diphosphonate therapy of Paget's disease of bone
52. Hypercalciuria in children severely affected with osteogenesis imperfecta
53. Diphosphonate therapy in nephrocalcinosis
54. A comparison of observational studies and randomized, controlled trials